4101. Primary tumor resection with or without metastasectomy for left- and right-sided stage IV colorectal cancer: an instrumental variable analysis.
作者: Yi-Chen Yao.;Jun-Quan Chen.;Ling Yin.;Wu-Hao Lin.;Jian-Hong Peng.;Wen-Hua Fan.
来源: BMC Gastroenterol. 2022年22卷1期114页
Whether primary tumor location (PTL) is predictive of survival benefits following primary tumor resection plus metastasectomy (PMTR) and primary tumor resection (PTR) alone in stage IV colorectal cancer patients is not known. We sought to address this issue by employing instrumental variable analysis to evaluate the efficacy of PMTR and PTR with stratification for primary tumor location in stage IV colorectal cancer patients.
4102. Early changes in laboratory tests predict liver function damage in patients with moderate coronavirus disease 2019: a retrospective multicenter study.
作者: Yiting Wang.;Dandan Gao.;Xuewen Li.;Panyang Xu.;Qi Zhou.;Junguo Yin.;Jiancheng Xu.
来源: BMC Gastroenterol. 2022年22卷1期113页
Most patients with coronavirus disease 2019 demonstrate liver function damage. In this study, the laboratory test data of patients with moderate coronavirus disease 2019 were used to establish and evaluate an early prediction model to assess the risk of liver function damage.
4103. Performance of a multicompounds nutraceutical formulation in patients with symptomatic uncomplicated diverticular disease.
作者: Giovanni Brandimarte.;Giovanni V Frajese.;Stefano Bargiggia.;Danilo Castellani.;Andrea Cocco.;Raffaele Colucci.;Enrica Evangelista.;Antonietta G Gravina.;Domenico Napoletano.;Elisabetta Nardi.;Tammaro Maisto.;Antonino Morabito.;Giuseppe Pianese.;Antonio Romano.;Rodolfo Sacco.;Luca Sediari.;Nicola Sinnona.;Lorenza Tifi.;Alessandro D'Avino.;Walter Elisei.;Antonio Tursi.
来源: Minerva Gastroenterol (Torino). 2022年68卷2期216-222页
Symptomatic uncomplicated diverticular disease (SUDD) is a recognized clinical condition characterized by abdominal pain and changes in bowel habits, attributed to diverticula but without macroscopic signs of diverticulitis. There is no consensus about the management of these patients. Enteroflegin®, an association of natural active ingredients, could be effective in the treatment of those patients.
4104. Chronic pancreatitis for the clinician: complications and special forms of the disease. Interdisciplinary position paper of the Catalan Society of Digestology (SCD) and the Catalan Pancreatic Society (SCPanc).
作者: Xavier Molero.;Juan R Ayuso.;Joaquim Balsells.;Jaume Boadas.;Juli Busquets.;Anna Casteràs.;Mar Concepción.;Míriam Cuatrecasas.;Gloria Fernàndez Esparrach.;Esther Fort.;Francisco Garcia Borobia.;Àngels Ginès.;Lucas Ilzarbe.;Carme Loras.;Miquel Masachs.;Xavier Merino.;Jorge J Olsina.;Valentí Puig-Diví.;Sílvia Salord.;Teresa Serrano.;Eva C Vaquero.
来源: Minerva Gastroenterol (Torino). 2024年70卷2期208-224页
Chronic pancreatitis tends to develop a number of complications that may constitute the form of presentation of the disease. Some societies have issued guidelines for diagnosis and treatment of chronic pancreatitis complications, but the level of evidence for any topic is usually low and recommendations tend to be weak. We aimed to provide defined position statements for the clinician based on updated review of published literature and on multidisciplinary expert agreement. The goal was to propose defined terminology and rational diagnostic/therapeutic circuits based on current knowledge. To this end 14 sections related to complications and special forms of chronic pancreatitis (early chronic, groove and autoimmune pancreatitis) were reviewed by 21 specialists from 6 different fields to generate 32 statements. Featured statements assert common bile duct stenosis does not require invasive treatment (endoscopic or surgical) unless cholestasis, cholangitis, lithiasis or other symptoms develop. Pancreatic duct strictures and calculi should be approached (after ruling out malignancy) if causing pain, pancreatitis, pseudocysts or other complications. Treatment of symptomatic pseudocysts must be individualized, considering associated main duct stenosis, vascular and pericystic complications. Higher risk conditions for pancreatic cancer are advance age, smoking, genetic background, recent diagnosis of chronic pancreatitis or diabetes, and appearance of new symptoms. Groove pancreatitis can initially be treated with conservative measures. Both prednisolone or rituximab can induce remission and maintenance of autoimmune pancreatitis. Internal fistula, vascular complications, bacterial overgrowth, osteoporosis and renal lithiasis require specific therapeutic approaches.
4105. Observation on the effect and effective rate of contrast-enhanced ultrasonography in interventional therapy for primary hepatocellular carcinoma.
作者: Peipei Wang.;Wei Yan.;Xuesen Liu.;Yang Yang.
来源: Minerva Gastroenterol (Torino). 2022年68卷3期352-354页 4106. Use of catheter-based cholangioscopy in the diagnosis of indeterminate stenosis: a multicenter experience.
作者: Socrate Pallio.;Emanuele Sinagra.;Alessio Santagati.;Fabio D'Amore.;Giancarlo Pompei.;Giuseppe Conoscenti.;Fabio Romeo.;Eleonora Borina.;Giuseppinella Melita.;Francesca Rossi.;Marcello Maida.;Rita Alloro.;Ilaria Tarantino.;Dario Raimondo.
来源: Minerva Gastroenterol (Torino). 2024年70卷1期29-35页
Direct bile ducts visualization through cholangioscopy has gained popularity due to its better diagnostic accuracy than a standard ERCP in indeterminate biliary stricture.
4107. Characterizing reflux on high resolution esophageal manometry with impedance.
In some patients, reflux at esophagogastric junction (EGJ) can be seen on the impedance portion of the high-resolution esophageal manometry with impedance (HREMI) studies. How this correlates with reflux on conventional esophageal reflux monitoring studies is unknown. We aimed to: (1) determine prevalence of reflux seen on HREMI, (2) correlate reflux during HREMI with reflux on esophageal reflux monitoring studies.
4108. Correction to: Increasing newly diagnosed inflammatory bowel disease and improving prognosis in China: a 30-year retrospective study from a single centre.
作者: Hong Lv.;Meng Jin.;Huimin Zhang.;Xuanfu Chen.;Meixu Wu.;Mingyue Guo.;Runing Zhou.;Zheng Wang.;Hong Yang.;Jiaming Qian.
来源: BMC Gastroenterol. 2022年22卷1期109页 4109. Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy.
作者: Junpeng Luo.;Zhimei Huang.;Murong Wang.;Tian Li.;Jinhua Huang.
来源: BMC Gastroenterol. 2022年22卷1期108页
Current study aims to determine the prognostic value of Multiparameter MRI after combined Lenvatinib and TACE therapy in patients with advanced unresectable hepatocellular carcinoma (HCC).
4110. Prevalence of constipation and use of laxatives, and association with risk factors among older patients during hospitalization: a cross sectional study.
作者: Hanne Konradsen.;Veronica Lundberg.;Jan Florin.;Anne-Marie Boström.
来源: BMC Gastroenterol. 2022年22卷1期110页
Many older patients experience constipation as a bothersome symptom with a negative impact on quality of life. During hospitalization, the focus is often on the reason for admission with the risk that other health problems are not prioritized. The aim of the study was to describe the prevalence of constipation and use of laxatives among older hospitalized patients and to investigate the associations with demographic factors, risk assessments and prescribed medications.
4111. Consensus care recommendations for alfapump® in cirrhotic patients with refractory or recurrent ascites.
作者: Niels Kristian Aagaard.;Massimo Malago.;Andrea De Gottardi.;Michael Thomas.;Gerd Sauter.;Cornelius Engelmann.;David Aranovich.;Michal Cohen.;Thierry Thévenot.;Thomas Ehmann.;Jeroen Capel.;Paolo Angeli.;Rajiv Jalan.;Guido Stirnimann.
来源: BMC Gastroenterol. 2022年22卷1期111页
The alfapump® is an implantable class III medical device that pumps ascitic fluid from the peritoneal space to the urinary bladder from where it is excreted. The pump reduces or abrogates the need for repeated paracentesis in patients with recurrent or refractory ascites.
4113. A novel duodenal-release formulation of caraway oil and L-menthol is a safe, effective and well tolerated therapy for functional dyspepsia.
作者: Brian E Lacy.;William D Chey.;Michael S Epstein.;Syed M Shah.;Patrick Corsino.;Linda R Zeitzoff.;Brooks D Cash.
来源: BMC Gastroenterol. 2022年22卷1期105页
A randomized, placebo-controlled clinical trial (FDREST) of a novel formulation of caraway oil and L-menthol (COLM-SST) demonstrated symptom relief in patients with functional dyspepsia (FD). Two follow-up studies were conducted to evaluate patient satisfaction, self-regulated dosing, and long-term safety data: FDACT, Functional Dyspepsia Adherence and Compliance Trial, and FDSU36, Functional Dyspepsia Safety Update at 36 months.
4114. Solitary rectal ulcer transformation to cap polyposis in a 15-year-old child.
作者: Abdolreza Emami.;Javad Shokri Shirvani.;Akramasadat Hosseini.;Seyed Hossein Hamidi.
来源: BMC Gastroenterol. 2022年22卷1期104页
Cap polyposis (CP) is a benign, non-malignant inflammatory disease that affects the rectum. It usually occurs during the 5th decade of life, but children could also be affected. Its specific pathology is unknown. Due to the clinical, endoscopic, and histologic similarities with other disorders such as inflammatory bowel disease, a thorough histologic evaluation is critical to avoid unnecessary interventions. This study presents a 15-year-old child with a previously reported case of solitary rectal ulcer (SRU) that developed into CP determined by colonoscopy and histologic findings.
4115. Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial.
作者: Nooshin Naghibzadeh.;Fatemeh Salmani.;Samira Nomiri.;Tahmine Tavakoli.
来源: BMC Gastroenterol. 2022年22卷1期107页
The goal of this study was to investigate the effects of treatment with Saccharomyces boulardii and Lactobacillus reuteri on the eradication of Helicobacter pylori and Adverse effects (AEs) of the treatment.
4116. Are gastrointestinal symptoms associated with higher risk of Mortality in COVID-19 patients? A systematic review and meta-analysis.
Gastrointestinal symptoms have been reported in patients with COVID-19. Several clinical investigations suggested that gastrointestinal symptoms were associated with disease severity of COVID-19. However, the relevance of gastrointestinal symptoms and mortality of COVID-19 remains largely unknown. We aim to investigate the relationship between gastrointestinal symptoms and COVID-19 mortality.
4117. Protein-losing gastroenteropathy complicated with asymptomatic primary biliary cholangitis, refractory to immunosuppressant, and improved by Helicobacter pylori eradication: a case report.
作者: Misako Tanaka.;Hideto Kawaratani.;Ryuichi Noguchi.;Aritoshi Koizumi.;Akihiko Shibamoto.;Kosuke Kaji.;Naotaka Shimozato.;Kuniyuki Kojima.;Yoshiaki Nishimura.;Hitoshi Yoshiji.
来源: BMC Gastroenterol. 2022年22卷1期101页
Protein-losing gastroenteropathy (PLGE) is a syndrome with a chief complaint of hypoalbuminemia, which occurs due to plasma protein leakage in the gastrointestinal tract, leading to general edema, ascites, and pleural effusions.
4118. Long-term survival of a patient with liver metastases from clear cell gastric adenocarcinoma after multimodality treatment including interventional oncology techniques: case report.
Gastric cancer (GC) is the fourth most common cancer and the third leading cancer-related cause of death worldwide since most patients are diagnosed at an advanced stage. The majority of GCs are adenocarcinomas (ACs), and the poorly characterized clear cell AC represents a unique subgroup of GCs and is an independent marker of poor prognosis. Even though the prognosis for patients with advanced GC is poor we present a report of a patient with long-term survival despite having liver metastases from clear cell gastric AC.
4119. The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial.
作者: Sara Ebrahimi-Mousavi.;Seyed Moayed Alavian.;Amir Ali Sohrabpour.;Fatemeh Dashti.;Kurosh Djafarian.;Ahmad Esmaillzadeh.
来源: BMC Gastroenterol. 2022年22卷1期102页
Given the increasing prevalence of non-alcoholic fatty liver disease, it is necessary to find an easy and cost-effective method in its management and treatment. Probiotics are a group of living microorganisms that might affect NAFLD through the intestinal-liver axis. The present clinical trial aims to examine the effect of probiotic yogurt consumption on liver enzymes, steatosis and liver fibrosis in patients with NAFLD.
|